Mutagenic potential of anti-herpes agents was written by De Clercq, E.; Cassiman, J. J.. And the article was included in Life Sciences on January 20,1986.Reference of 69256-17-3 The following contents are mentioned in the article:
A number of anti-herpes agents which are either licensed for clin. use (acyclovir [59277-89-3]) or subject to clin. studies ((E)-5-(2-bromovinyl)-2′-deoxyuridine [69304-47-8], 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl-5-iodocytosine [69123-90-6], and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [82410-32-0]) or under preclin. investigation (1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil (FIAU) [69123-98-4], 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-methyluracil [69256-17-3], 9-(3,4-dihydroxybutyl)guanine [83470-64-8], (E)-5-(2-bromovinyl)-2′-deoxycytidine [74131-09-2], (E)-5-(bromovinyl)-1-β-D-arabinofuranosyluracil [77181-69-2], carbocyclic bromovinyldeoxyuridine [95463-56-2], (E)-5-(2-bromovinyl)uracil [69304-49-0], and (E)-5-(2-bromovinyl)uridine [86391-68-6]) were evaluated for their ability to induce sister chromatid exchange (SCE), an indicator of mutagenesis. SCE was scored on metaphasic chromosomes of human lymphocytes which had been exposed to 5-bromo-2-deoxyuridine and varying concentrations of the test compounds The antiviral assays were based on the inhibition of the cytopathogenicity of herpes simplex virus for human diploid fibroblasts. Most compounds, e.g., acyclovir, bromovinyldeoxyuridine, or carbocyclic bromovinyldeoxyuridine, either did not induce SCE or only did so at concentrations far above their min. antiviral concentrations However, FIAU and dihydroxypropoxymethylguanine affected the SCE rate at a concentration (≥4.5 μg/mL) that is readily achievable in blood following i.v. injection. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Reference of 69256-17-3).
1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Reference of 69256-17-3
69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3